Huawei is making a deliberate bet on artificial intelligence for drug discovery, announcing plans to deepen partnerships with pharmaceutical companies across the entire development pipeline. The company's healthcare president, William Zhang, confirmed to Reuters that Huawei's current AI drug projects run predominantly with domestic Chinese drugmakers, and the company intends to expand these collaborations from early research through clinical trials to final implementation.

What Is Huawei Actually Offering Pharma Companies?

Huawei's pharmaceutical AI strategy centers on a specific infrastructure play. The company sells compound screening tools alongside its Ascend and Kunpeng chips, domestically developed hardware that Huawei has been building since US sanctions forced the company to pursue self-reliant alternatives. This infrastructure-first approach differs markedly from how competitors like Nvidia position their AI drug discovery offerings.

The most concrete example of Huawei's work is an agreement announced in May with Guangzhou Pharmaceutical Holdings, a state-owned enterprise. Huawei described the arrangement as the industry's first production validation of independently developed AI drug research models adapted to run on Ascend and Kunpeng hardware. However, the AI drug research models themselves belong to StoneWise, a Beijing-based AI drug design company. Huawei's role was providing the silicon and completing the software work required to run StoneWise's models on its own chips, which represents infrastructure work rather than scientific development.

Huawei also developed the Pangu drug molecule model, released in 2021 in partnership with the Chinese Academy of Sciences. The model was trained on 1.7 billion existing compounds to predict how molecules bind to biological targets. Additionally, the company maintains a collaboration with Yunnan Baiyao dating to 2022, under which the drugmaker contributes botanical compound libraries while Huawei provides cloud computing capacity and AI tools.

How Does Huawei's Approach Compare to Global Competitors?

The competitive landscape reveals significant asymmetry. Nvidia has established AI partnerships with major global pharmaceutical companies including Eli Lilly and Novo Nordisk. The Lilly arrangement alone involves a co-innovation laboratory with up to one billion US dollars committed jointly over five years. Against that benchmark, Huawei's disclosed pharmaceutical work consists of one three-party ecosystem agreement at proof-of-concept stage and a four-year-old cooperation deal.

What Huawei does have in its favor is a supportive policy environment. Biopharmaceuticals were designated an emerging pillar industry in this year's government work report, and AI applications in pharmaceuticals are written into China's fifteenth five-year plan. A state-backed body inaugurated in June lists Huawei on the supply side of the AI drug development ecosystem, alongside companies such as Kingdee and XtalPi.

What Are the Broader Challenges Facing AI Drug Discovery?

The pharmaceutical industry has invested approximately sixty billion US dollars into AI drug discovery globally. Yet despite this massive investment, no AI-discovered drug has yet received regulatory approval anywhere in the world. However, progress is accelerating: the number of AI-derived candidates in development pipelines had reached 179 by June, compared with just four in 2017, and nine have advanced to Phase III trials, the most rigorous stage of human testing.

Huawei's domestic orientation also reflects an external constraint. US export guidance issued last year indicated that using Huawei's Ascend accelerators is likely to breach American controls, which significantly limits the international addressable market for a product pitch built around that hardware.

How Are Other Companies Advancing AI in Drug Development?

Beyond Huawei, other organizations are making significant strides in AI-powered pharmaceutical innovation. IQVIA, a leading global provider of clinical research services and healthcare intelligence, has won multiple industry awards this year for its AI solutions across drug development and healthcare operations. These recognitions span several critical areas:

• Literature Review Acceleration: IQVIA's Literature AI Platform demonstrated 100% recall in search, 93% or higher precision in document screening, and more than a 90% reduction in screening workload compared with manual review, earning an American Business Awards Gold Stevie for Technical Innovation of the Year in Healthcare Technology.
• Privacy-Preserving Data Use: IQVIA's Privacy Analytics Platform won a MedTech Breakthrough Award for Best Compliance Solution and is deployed within the NHS Federated Data Platform in England, which integrates health data from 55 million patients and has enabled more than 110,000 additional procedures.
• Clinical Trial Optimization: IQVIA's Interactive Response Technology Supply Automation Value Engine reduced instances when trial sites ran out of needed medicines by 76% and cut drug supply deliveries by 73%, earning an American Business Awards Silver Stevie.
• Patient Identification: IQVIA's AI-enabled clinical decision support tool, developed in collaboration with Breakthrough T1D, reduced screening burden by 99.5% and delivered a 127-fold improvement in identifying potential type 1 diabetes patients, winning an AI Breakthrough Award for Predictive Modeling Solution of the Year.

"As we further deepen our research into AI in the medical field, we'll have more collaboration and results emerging with pharmaceutical companies from drug manufacturing to clinical to final implementation," said William Zhang, president of Huawei's healthcare business unit.

William Zhang, President of Healthcare Business Unit, Huawei

Why Should You Care About Huawei's AI Pharma Strategy?

Huawei's push into AI drug discovery signals a broader geopolitical and technological shift in pharmaceutical innovation. The company's strategy reveals how sanctions and supply chain fragmentation are reshaping where and how drug discovery happens. Rather than competing head-to-head with Nvidia on global partnerships, Huawei is building a domestic ecosystem with Chinese drugmakers and state support, creating an alternative pipeline for AI-driven pharmaceutical development.

This matters because it demonstrates that AI drug discovery is no longer a single-track race dominated by Western companies and their partners. Multiple regional approaches are emerging, each with different constraints, resources, and policy backing. The ultimate winners will likely be those who can move from proof-of-concept to actual drug candidates entering clinical trials, a milestone that remains elusive across the entire industry despite decades of AI hype.